These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
381 related articles for article (PubMed ID: 27873232)
1. Evidence-Based Revised View of the Pathophysiology of Preeclampsia. Ahmed A; Rezai H; Broadway-Stringer S Adv Exp Med Biol; 2017; 956():355-374. PubMed ID: 27873232 [TBL] [Abstract][Full Text] [Related]
2. Molecular mechanisms and therapeutic implications of the carbon monoxide/hmox1 and the hydrogen sulfide/CSE pathways in the prevention of pre-eclampsia and fetal growth restriction. Ahmed A Pregnancy Hypertens; 2014 Jul; 4(3):243-4. PubMed ID: 26104642 [TBL] [Abstract][Full Text] [Related]
3. Negative regulation of soluble Flt-1 and soluble endoglin release by heme oxygenase-1. Cudmore M; Ahmad S; Al-Ani B; Fujisawa T; Coxall H; Chudasama K; Devey LR; Wigmore SJ; Abbas A; Hewett PW; Ahmed A Circulation; 2007 Apr; 115(13):1789-97. PubMed ID: 17389265 [TBL] [Abstract][Full Text] [Related]
4. A Narrative Review on the Pathophysiology of Preeclampsia. Torres-Torres J; Espino-Y-Sosa S; Martinez-Portilla R; Borboa-Olivares H; Estrada-Gutierrez G; Acevedo-Gallegos S; Ruiz-Ramirez E; Velasco-Espin M; Cerda-Flores P; Ramirez-Gonzalez A; Rojas-Zepeda L Int J Mol Sci; 2024 Jul; 25(14):. PubMed ID: 39062815 [TBL] [Abstract][Full Text] [Related]
5. New insights into the etiology of preeclampsia: identification of key elusive factors for the vascular complications. Ahmed A Thromb Res; 2011 Feb; 127 Suppl 3():S72-5. PubMed ID: 21262447 [TBL] [Abstract][Full Text] [Related]
6. Dysregulation of anti-angiogenic agents (sFlt-1, PLGF, and sEndoglin) in preeclampsia--a step forward but not the definitive answer. Foidart JM; Schaaps JP; Chantraine F; Munaut C; Lorquet S J Reprod Immunol; 2009 Nov; 82(2):106-11. PubMed ID: 19853925 [TBL] [Abstract][Full Text] [Related]
7. Resveratrol inhibits release of soluble fms-like tyrosine kinase (sFlt-1) and soluble endoglin and improves vascular dysfunction - implications as a preeclampsia treatment. Hannan NJ; Brownfoot FC; Cannon P; Deo M; Beard S; Nguyen TV; Palmer KR; Tong S; Kaitu'u-Lino TJ Sci Rep; 2017 May; 7(1):1819. PubMed ID: 28500309 [TBL] [Abstract][Full Text] [Related]
8. Effects of pravastatin on angiogenic and placental hypoxic imbalance in a mouse model of preeclampsia. Saad AF; Kechichian T; Yin H; Sbrana E; Longo M; Wen M; Tamayo E; Hankins GD; Saade GR; Costantine MM Reprod Sci; 2014 Jan; 21(1):138-45. PubMed ID: 23749761 [TBL] [Abstract][Full Text] [Related]
9. Can the biology of VEGF and haem oxygenases help solve pre-eclampsia? Ahmed A; Cudmore MJ Biochem Soc Trans; 2009 Dec; 37(Pt 6):1237-42. PubMed ID: 19909254 [TBL] [Abstract][Full Text] [Related]
10. Increased risk for the development of preeclampsia in obese pregnancies: weighing in on the mechanisms. Spradley FT; Palei AC; Granger JP Am J Physiol Regul Integr Comp Physiol; 2015 Dec; 309(11):R1326-43. PubMed ID: 26447211 [TBL] [Abstract][Full Text] [Related]
11. Therapeutic potential of statins and the induction of heme oxygenase-1 in preeclampsia. Ramma W; Ahmed A J Reprod Immunol; 2014 Mar; 101-102(100):153-160. PubMed ID: 24503248 [TBL] [Abstract][Full Text] [Related]
12. Unravelling the theories of pre-eclampsia: are the protective pathways the new paradigm? Ahmed A; Ramma W Br J Pharmacol; 2015 Mar; 172(6):1574-86. PubMed ID: 25303561 [TBL] [Abstract][Full Text] [Related]
13. [Potential value of placental angiogenic factors as biomarkers in preeclampsia for clinical physicians]. Boulanger H; Lefèvre G; Ahriz Saksi S; Achiche J; Bailleul S; Ekoukou D; Drouin D; Sault C; Stawiarski N; Dupuis E Nephrol Ther; 2019 Nov; 15(6):413-429. PubMed ID: 30935786 [TBL] [Abstract][Full Text] [Related]
14. Heme Oxygenase-1 Is Not Decreased in Preeclamptic Placenta and Does Not Negatively Regulate Placental Soluble fms-Like Tyrosine Kinase-1 or Soluble Endoglin Secretion. Tong S; Kaitu'u-Lino TJ; Onda K; Beard S; Hastie R; Binder NK; Cluver C; Tuohey L; Whitehead C; Brownfoot F; De Silva M; Hannan NJ Hypertension; 2015 Nov; 66(5):1073-81. PubMed ID: 26324507 [TBL] [Abstract][Full Text] [Related]
15. Activating Transcription Factor 3 Is Reduced in Preeclamptic Placentas and Negatively Regulates sFlt-1 (Soluble fms-Like Tyrosine Kinase 1), Soluble Endoglin, and Proinflammatory Cytokines in Placenta. Kaitu'u-Lino TJ; Brownfoot FC; Hastie R; Chand A; Cannon P; Deo M; Tuohey L; Whitehead C; Hannan NJ; Tong S Hypertension; 2017 Nov; 70(5):1014-1024. PubMed ID: 28947613 [TBL] [Abstract][Full Text] [Related]
16. Effects of simvastatin, rosuvastatin and pravastatin on soluble fms-like tyrosine kinase 1 (sFlt-1) and soluble endoglin (sENG) secretion from human umbilical vein endothelial cells, primary trophoblast cells and placenta. Brownfoot FC; Tong S; Hannan NJ; Hastie R; Cannon P; Kaitu'u-Lino TJ BMC Pregnancy Childbirth; 2016 May; 16():117. PubMed ID: 27207105 [TBL] [Abstract][Full Text] [Related]